IKZF1plus alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial

被引：6

作者：

Ito, Yoshikiyo ^{[1
,18
]}

Ozawa, Hidetoshi ^{[2
]}

Eto, Tetsuya ^{[3
]}

Miyamoto, Toshihiro ^{[4
,5
]}

Kamimura, Tomohiko ^{[6
]}

Ogawa, Ryosuke ^{[7
]}

Uchida, Naoyuki ^{[8
]}

Wake, Atsusi ^{[9
]}

Fujisaki, Tomoaki ^{[10
]}

Ohno, Yuju ^{[11
]}

Takase, Ken ^{[12
,13
]}

Okumura, Hirokazu ^{[14
,15
]}

Takamatsu, Yasushi ^{[16
]}

Kawano, Noriaki ^{[17
]}

Akashi, Koichi ^{[4
]}

Nagafuji, Koji ^{[2
]}

机构：

[1] Imamura Gen Hosp, Dept Hematol, Kagoshima, Japan

[2] Kurume Univ, Dept Med, Div Hematol & Oncol, Sch Med, Kurume, Japan

[3] Hamanomachi Hosp, Dept Hematol, Fukuoka, Japan

[4] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Japan

[5] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Div Hematol, Kanazawa, Japan

[6] Harasanshin Hosp, Dept Hematol, Fukuoka, Japan

[7] Japan Community Hlth Care Org JCHO Kyushu Hosp, Dept Hematol & Oncol, Kitakyushu, Japan

[8] Toranomon Gen Hosp, Dept Hematol, Tokyo, Japan

[9] Toranomon Hosp Kajigaya, Dept Hematol, Kawasaki, Japan

[10] Matsuyama Red Cross Hosp, Dept Hematol, Matsuyama, Japan

[11] Kitakyushu Municipal Med Ctr, Dept Hematol, Kitakyushu, Japan

[12] Natl Hosp Org Kyushu Med Ctr, Dept Hematol, Fukuoka, Japan

[13] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Fukuoka, Japan

[14] Toyama Prefectural Cent Hosp, Dept Hematol, Toyama, Japan

[15] Minamisoma Municipal Gen Hosp, Dept Hematol, Minamisoma, Japan

[16] Fukuoka Univ Hosp, Dept Internal Med, Div Med Oncol Hematol & Infect Dis, Fukuoka, Japan

[17] Miyazaki Prefectural Hosp, Dept Hematol, Miyazaki, Japan

[18] Imamura Gen Hosp, Dept Hematol, 11-23 Kamoike Shin Cho, Kagoshima, Kagoshima 8900064, Japan

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2023年 / 111卷 / 01期

关键词：

IKZF1(plus); Philadelphia-positive ALL; B-CELL PRECURSOR; KINASE DOMAIN MUTATIONS; IMATINIB RESISTANCE; IKZF1; DELETIONS; HYPER-CVAD; PHASE-II; CHROMOSOME; CHEMOTHERAPY; THERAPY; ADULTS;

D O I：

10.1111/ejh.13972

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: The prognostic significance of IKZF1(plus) in adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients had remained to be clarified.Methods: We conducted a prospective, multicenter study, the ALL/MRD2008 trial, and investigated the clinical significance of IKZF1(plus).Results: From December 2008 to November 2013, 38 untreated Ph+ ALL patients were enrolled. At the end of the induction, 97.4% of patients (37/38) achieved complete hematological remission, with MRD-negativity of 48.6% (18/37). There were 19 patients with IKZF1(plus), 13 with IKZF1 deletion alone (Delta IKZF1) and 4 with no IKZF1 deletions (no Delta IKZF1). The probability of 3-year DFS and OS in these Ph+ ALL patients were 50% (95% confidence interval [CI], 33-65) and 55% (95% CI, 38-69), respectively. There was no significant difference between IKZF1(plus), Delta IKZF1, and no Delta IKZF1 in DFS (47%, 54%, 75% [p = .63]) or OS (47%, 62%, NA [p = .39]).Conclusions: We revealed no relationship between IKZF1(plus) status and survival outcomes in Ph+ ALL patients treated with imatinib/dasatinib combination chemotherapy. Further investigations are warranted to clarify the prognostic significance of IKZF1(plus) in adult Ph+ ALL patients.

引用

页码：103 / 112

页数：10

共 42 条

[1] Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia [J].

Cataland, SR ;

Daugherty, CK ;

Weseman, EC ;

Larson, RA .

LEUKEMIA & LYMPHOMA, 2001, 41 (3-4) :297-307

[2] IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol [J].

Dorge, Petra ;

Meissner, Barbara ;

Zimmermann, Martin ;

Moericke, Anja ;

Schrauder, Andre ;

Bouquin, Jean-Pierre ;

Schewe, Denis ;

Harbott, Jochen ;

Teigler-Schlegel, Andrea ;

Ratei, Richard ;

Ludwig, Wolf-Dieter ;

Koehler, Rolf ;

Bartram, Claus R. ;

Schrappe, Martin ;

Stanulla, Martin ;

Cario, Gunnar .

HAEMATOLOGICA, 2013, 98 (03) :428-432

[3] The biology and therapy of adult acute lymphoblastic leukemia [J].

Faderl, S ;

Jeha, S ;

Kantarjian, HM .

CANCER, 2003, 98 (07) :1337-1354

[4] Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia [J].

Fedullo, Anna Lucia ;

Messina, Monica ;

Elia, Loredana ;

Piciocchi, Alfonso ;

Gianfelici, Valentina ;

Lauretti, Alessia ;

Soddu, Stefano ;

Puzzolo, Maria Cristina ;

Minotti, Clara ;

Ferrara, Felicetto ;

Martino, Bruno ;

Chiusolo, Patrizia ;

Calafiore, Valeria ;

Paolini, Stefania ;

Vignetti, Marco ;

Vitale, Antonella ;

Guarini, Anna ;

Foa, Robin ;

Chiaretti, Sabina .

HAEMATOLOGICA, 2019, 104 (02) :312-318

[5] UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia [J].

Fielding, Adele K. ;

Rowe, Jacob M. ;

Buck, Georgina ;

Foroni, Letizia ;

Gerrard, Gareth ;

Litzow, Mark R. ;

Lazarus, Hillard ;

Luger, Selina M. ;

Marks, David I. ;

McMillan, Andrew K. ;

Moorman, Anthony V. ;

Patel, Bella ;

Paietta, Elisabeth ;

Tallman, Martin S. ;

Goldstone, Anthony H. .

BLOOD, 2014, 123 (06) :843-850

[6] Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults [J].

Foa, Robin ;

Bassan, Renato ;

Vitale, Antonella ;

Elia, Loredana ;

Piciocchi, Alfonso ;

Puzzolo, Maria-Cristina ;

Canichella, Martina ;

Viero, Piera ;

Ferrara, Felicetto ;

Lunghi, Monia ;

Fabbiano, Francesco ;

Bonifacio, Massimiliano ;

Fracchiolla, Nicola ;

Di Bartolomeo, Paolo ;

Mancino, Alessandra ;

De Propris, Maria-Stefania ;

Vignetti, Marco ;

Guarini, Anna ;

Rambaldi, Alessandro ;

Chiaretti, Sabina .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (17) :1613-1623

[7] Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia [J].

Fujisawa, Shin ;

Mizuta, Shuichi ;

Akiyama, Hideki ;

Ueda, Yasunori ;

Aoyama, Yasutaka ;

Hatta, Yoshihiro ;

Kakihana, Kazuhiko ;

Dobashi, Nobuaki ;

Sugiura, Isamu ;

Onishi, Yasushi ;

Maeda, Tomoya ;

Imai, Kiyotoshi ;

Ohtake, Shigeki ;

Miyazaki, Yasushi ;

Ohnishi, Kazunori ;

Matsuo, Keitaro ;

Naoe, Tomoki .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (04) :367-374

[8] THE IKAROS GENE IS REQUIRED FOR THE DEVELOPMENT OF ALL LYMPHOID LINEAGES [J].

GEORGOPOULOS, K ;

BIGBY, M ;

WANG, JH ;

MOLNAR, A ;

WU, P ;

WINANDY, S ;

SHARPE, A .

CELL, 1994, 79 (01) :143-156

[9] Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia [J].

Hofmann, WK ;

Komor, M ;

Wassmann, B ;

Jones, LC ;

Gschaidmeier, H ;

Hoelzer, D ;

Koeffler, HP ;

Ottmann, OG .

BLOOD, 2003, 102 (02) :659-661

[10] Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology [J].

Hovorkova, Lenka ;

Zaliova, Marketa ;

Venn, Nicola C. ;

Bleckmann, Kirsten ;

Trkova, Marie ;

Potuckova, Eliska ;

Vaskova, Martina ;

Linhartova, Jana ;

Polakova, Katerina Machova ;

Fronkova, Eva ;

Muskovic, Walter ;

Giles, Jodie E. ;

Shaw, Peter J. ;

Cario, Gunnar ;

Sutton, Rosemary ;

Stary, Jan ;

Trka, Jan ;

Zuna, Jan .

BLOOD, 2017, 129 (20) :2771-2781

← 1 2 3 4 5 →